March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 25, 2026

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Conexiant

January 28, 2026

IPF Cough: Opioid-Based Approach Tested

Researchers examine oral nalbuphine for chronic cough in IPF, using objective digital monitoring and patient-reported measures.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant

December 05, 2025

On the Edge of a Measles Comeback?

New analysis examines rising U.S. measles outbreaks, associated clinical risks, and the potential loss of measles-elimination status.

KFF Health News

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

December 04, 2025

FDA Approves Biologic for Nerve Repair

A newly licensed biologic offers a novel approach to repairing complex peripheral nerve injuries across pediatric and adult populations.

Conexiant

December 02, 2025

FDA Clears Rapid Bordetella PCR Test

The assay detects and differentiates key Bordetella species at the point of care, providing rapid results that support timely pertussis evaluation.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant